← Back to Episodes
PODCAST

Coffee, Bones, and the Ultrasound Finding You Should Know About

August 7, 2026·9:13·Episode 97

Quick Summary

This Friday episode covers three new studies: a Turkish study on coffee and hot flash severity, a bone density trial testing a specific form of vitamin D in postmenopausal women with osteopenia, and Indonesian ultrasound research that highlights an endometrial thickness measurement every postmenopausal woman deserves to understand. Lenses used: research credibility and lifestyle.

Coffee, Bones, and the Ultrasound Finding You Should Know About

0:000:00

Key Takeaways

  • ✦A 2026 Turkish study (Akbal et al.) found an association between coffee consumption and vasomotor symptom severity in postmenopausal women — but the study is observational, so correlation doesn't equal causation.
  • ✦Doxercalciferol (1α-hydroxyvitamin D2) showed measurable effects on spine and femur bone mineral density in postmenopausal women with osteopenia in a 2026 trial by Gallagher — worth asking your provider about if standard vitamin D supplementation hasn't moved your numbers.
  • ✦Endometrial thickness on ultrasound is a key screening marker: in postmenopausal women, a measurement above 4–5mm typically prompts further investigation, and the 2026 Indonesian study (Putra et al.) reinforces why baseline imaging matters across diverse populations.
  • ✦Not all vitamin D is the same — doxercalciferol is an activated precursor form that may act differently in the body than standard D3 supplements, which is relevant if you're managing bone density numbers.
  • ✦If you drink coffee and your hot flashes are severe, this study gives a reasonable prompt to experiment — track your symptoms for two weeks with and without, then decide based on your own data.

Episode Script

Thanks Toni. We've got a good one to wrap up the week — let's get into it.

I want to start with coffee, because I know that word just made at least half of you sit up a little straighter, possibly while holding a mug.

A study published in June 2026 out of Turkey — Akbal and colleagues, in case you want to look it up — looked at the relationship between coffee consumption and vasomotor symptom severity in postmenopausal women. Vasomotor symptoms meaning hot flashes and night sweats, the ones that make you kick off the covers at 2am and stand in front of the open refrigerator like it's a spa treatment.

So what did they find? Women who drank more coffee reported more severe vasomotor symptoms. That's the headline version, and it's the version that's already making the rounds in wellness spaces with the caption "put down the coffee, sis."

But here's where I want to slow down, because the study design matters. This is an observational study. The researchers asked women about their coffee habits and their symptoms — they didn't control for coffee intake or randomly assign anyone to drink more or less. That means they found an association, not a cause. And observational studies in menopause research are everywhere, which is great for generating hypotheses and genuinely maddening if you're trying to make actual decisions.

There are a few things that could be going on here. Women with more severe symptoms might reach for coffee more often because they're exhausted from not sleeping. Caffeine is a known vasodilator and can raise core body temperature slightly, which could theoretically lower the threshold for a flash. Or it could be that women who drink more coffee have other lifestyle factors — stress, less sleep, different dietary patterns — that also correlate with more severe symptoms. The study can't untangle that.

What I will say is this: if your hot flashes are severe and frequent, and you're a heavy coffee drinker, it is not unreasonable to run an experiment on yourself. Two weeks, cut back or cut out, track your symptoms honestly. That's not the same as saying coffee causes hot flashes. It's saying your body is a useful data source and coffee is a low-cost variable to test. The evidence doesn't say throw out your French press. It says this relationship is worth paying attention to.

The researchers were working with a Turkish population, which also matters — diet, lifestyle, and genetic factors vary across populations, and we shouldn't automatically generalize. But the question they're asking is a real one, and more rigorous work in this area would be genuinely useful.

Alright. Bones.

There's a 2026 paper from Gallagher — published on PubMed — looking at something called doxercalciferol, which is 1α-hydroxyvitamin D2. I want to spend a minute on this because it gets lost in the noise around generic "vitamin D" advice, and I think that's a problem.

Most of us, when we hear "take vitamin D for bone health," are thinking about standard vitamin D3 — cholecalciferol. You buy it at the drugstore, it's in most multivitamins, and it requires two conversion steps in your body before it becomes the active form your bones can actually use. The liver does one conversion, the kidneys do another.

Doxercalciferol is different. It's already been through one of those conversion steps. It's an activated precursor, which means your body has less work to do. That's potentially meaningful for postmenopausal women, especially anyone whose kidney function isn't optimal, because that final conversion step happens in the kidneys and can become less efficient with age.

The Gallagher study looked at efficacy and safety for spine and femur bone mineral density in postmenopausal women with osteopenia — meaning not yet at the fracture-risk threshold of osteoporosis, but already losing density. And the findings showed measurable effects on bone mineral density at both sites.

Now I want to be careful here, because this is one study and I haven't seen the full methods or sample size. What I will say is that this is the kind of research that should prompt a conversation with your provider if you have osteopenia and your bone density numbers haven't moved with standard supplementation. The question to ask is not "can I buy this at Target" — doxercalciferol is a prescription medication — but "is standard D3 actually the right tool for where I am right now."

This is also where I want to push back a little on the supplement industry framing around vitamin D, because what happens in practice is that women get told "take vitamin D" and they buy D3 gummies and assume the job is done. The reality is that different forms of vitamin D have different metabolic pathways, different conversion rates, and potentially different effects depending on your individual physiology. Not all vitamin D acts the same way in all bodies. That distinction almost never makes it into the five-minute appointment.

If you're tracking your bone density — and if you're postmenopausal, you should be — and if you're supplementing and not seeing movement, this study is a prompt to go back to your provider and ask specifically about your vitamin D metabolism and whether a different form might be worth trying. The kind of evidence your doctor would look at on a tool like OpenEvidence would include studies exactly like this one.

The third thing I want to cover today is a little different in flavor — it's less about what you do and more about what you know.

A 2026 study from Indonesia, Putra and colleagues, looked at endometrial thickness measurements on ultrasound across a multi-ethnic population of Indonesian women — comparing measurements in women with normal endometrium versus women with endometrial cancer.

Endometrial cancer is the most common gynecologic cancer in postmenopausal women, and the primary screening tool is transvaginal ultrasound measuring endometrial thickness. The threshold that typically prompts further investigation — biopsy, referral — is around 4 to 5 millimeters in a postmenopausal woman. Below that, the risk of cancer is low. Above that, it's not a diagnosis, but it's a signal that something warrants a closer look.

What this study adds is data from a multi-ethnic Indonesian population, which matters because most of the baseline data on endometrial thickness comes from Western European and North American cohorts. Whether those reference ranges translate cleanly across ethnic groups is a real question in gynecologic medicine, and it doesn't get asked often enough.

I think the reason I want to mention this study on a Friday — the "weekend wellness" frame — is not to send anyone into an anxiety spiral. It's because I've seen so many posts in menopause communities from women who had an ultrasound, were told a number, and had no idea what it meant or what question to ask next. Knowing that endometrial thickness is measured, knowing what the general threshold is, and knowing that it varies with whether you're on hormone therapy — progestogens specifically protect the endometrium, which is one reason why combined HRT exists — that's information that makes you a better advocate for yourself in an appointment.

If you've had a pelvic ultrasound in the last year or two and you don't know what your endometrial measurement was, it's worth asking. Not because something is probably wrong — statistically, it probably isn't — but because it's your data and you're allowed to have it.

That's the piece. Know the number. Know what it means. Ask.


Thanks for being here all week. It genuinely means something that you spend your mornings with Hot Flasher, and I don't take that lightly. If you're enjoying the show, please hit subscribe wherever you listen — it's the best way to make sure you don't miss an episode, and it helps more women find the show. Have a great weekend, and I'll see you Monday.


Sources curated automatically by the Hot Flasher pipeline.

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.